You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Prana Biotechnology Limited (PBT) is an Australian biotechnology company with a focus on the development of pharmaceutical products designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses Potential applications for PBTâ€™s MPAC (Metal-Protein Attenuating Compound) technology including Alzheimerâ€™s, Parkinsonâ€™s and Huntingtonâ€™s diseases and brain cancer.
Strategy Analysis: The Company's focus is the development of the disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's disease. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration. Prana's leadÂ compound PBT2Â has completedÂ Phase IIa clinical trial in patients with early Alzheimer's Disease. Planning is currently underway for a Phase IIb clinical trial of PBT2 in patients with mild to moderate Alzheimer's Disease. Prana is currently validating candidate leads from its MPAC library in the selection of PBT3 and PBT4 series compounds to be designated as follow ups of PBT2 in AD, or for use in secondary alternative indications..
Nick Swales, Regional Director, Newcastle Office, Rathbones 27/10/2014 |
â€śIf you want to have a better performance than the crowd, you must do things differently from the crowd.â€ť Sir John Templeton.
Ric Spooner (Chief Market Analyst, CMC Markets) 20/10/2014 |
Today, Australian investors will not have to go it alone buying stocks as they did for much of last week. Bargain hunters this morning will be supported by the morale boosting encouragement of a 3% turnaround in the German Dax and a 264 point rally in the Dow Jones.
Carl Richards, director of investor education at the BAM Alliance 17/10/2014 |
â€śAs odd as it may sound, the sooner you start treating your investments like you treat life, the happier youâ€™ll be with the outcome.â€ť
William H. Gross, Janus Capital Group 16/10/2014 |
â€śFinancial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding â€śminusâ€ť 10 basis points.â€ť
CMC Markets 8/10/2014 |
Share market indices around the globe are breaking down. While analysts cast around for reasons, itâ€™s clear that a time factor is in play. Simply put, many investors â€śfeelâ€ť a correction is overdue. How low could it go?
IMPORTANT: This information has been prepared without taking into account your objectives, financial situation or needs and you should consider if the information is appropriate for you before making an investment decision. Neither InvestSMART Financial Services Pty Ltd nor any of its Related Companies make any recommendations as to the merits of any investment opportunity referred to in its emails or its related websites. Product disclosure statements for financial products offered through InvestSMART can be downloaded from this website or obtained by contacting 1300 880 160. You should consider the product disclosure statement before making a decision about the product. All indications of performance returns are historical and can not be relied upon as an indicator for future performance.